PH27118A - Anticonvulsant compounds - Google Patents

Anticonvulsant compounds Download PDF

Info

Publication number: PH27118A
Authority: PH; Philippines
Prior art keywords: compound; difluoro; pharmaceutically; formula; alpyridine
Prior art date: 1989-04-21

Application number

PH40399A

Other languages

English (en)

Inventor

James Leroy Kelley

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-21

Filing date

1990-04-19

Publication date

1993-03-16

1990-04-19 Application filed by Wellcome Found filed Critical Wellcome Found

1993-03-16 Publication of PH27118A publication Critical patent/PH27118A/en

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 56
239000001961 anticonvulsive agent Substances 0.000 title description 9
229960003965 antiepileptics Drugs 0.000 title description 7
230000001773 anti-convulsant effect Effects 0.000 title description 6
238000002360 preparation method Methods 0.000 claims abstract description 20
238000000034 method Methods 0.000 claims abstract description 12
239000008194 pharmaceutical composition Chemical class 0.000 claims abstract description 3
238000006243 chemical reaction Methods 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
150000001412 amines Chemical class 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
150000002431 hydrogen Chemical class 0.000 claims description 4
PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims description 4
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000001153 fluoro group Chemical group F* 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
206010015037 epilepsy Diseases 0.000 abstract description 6
241000124008 Mammalia Species 0.000 abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 abstract 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000007787 solid Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 11
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
235000019439 ethyl acetate Nutrition 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
241000282414 Homo sapiens Species 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000000872 buffer Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
125000001309 chloro group Chemical group Cl* 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 6
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
239000008213 purified water Substances 0.000 description 5
-1 triazolopyridine Chemical class 0.000 description 5
HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
235000021355 Stearic acid Nutrition 0.000 description 4
230000037396 body weight Effects 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000008101 lactose Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000008117 stearic acid Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
QLILRKBRWXALIE-UHFFFAOYSA-N 3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1 QLILRKBRWXALIE-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
235000010288 sodium nitrite Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 2
125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000034308 Grand mal convulsion Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000000260 Warts Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
150000003927 aminopyridines Chemical class 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
238000004040 coloring Methods 0.000 description 2
150000004683 dihydrates Chemical class 0.000 description 2
239000012458 free base Substances 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
201000010153 skin papilloma Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
PQCUDKMMPTXMAL-UHFFFAOYSA-N (2,6-difluorophenyl)methanamine Chemical compound NCC1=C(F)C=CC=C1F PQCUDKMMPTXMAL-UHFFFAOYSA-N 0.000 description 1
LRFWYBZWRQWZIM-UHFFFAOYSA-N (2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC=C1F LRFWYBZWRQWZIM-UHFFFAOYSA-N 0.000 description 1
BTANRVKWQNVYAZ-SCSAIBSYSA-N (2R)-butan-2-ol Chemical compound CC[C@@H](C)O BTANRVKWQNVYAZ-SCSAIBSYSA-N 0.000 description 1
YKYIFUROKBDHCY-ONEGZZNKSA-N (e)-4-ethoxy-1,1,1-trifluorobut-3-en-2-one Chemical group CCO\C=C\C(=O)C(F)(F)F YKYIFUROKBDHCY-ONEGZZNKSA-N 0.000 description 1
QEASJVYPHMYPJM-UHFFFAOYSA-N 1,2-dihydrotriazol-5-one Chemical compound OC1=CNN=N1 QEASJVYPHMYPJM-UHFFFAOYSA-N 0.000 description 1
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
ZENKESXKWBIZCV-UHFFFAOYSA-N 2,2,4,4-tetrafluoro-1,3-benzodioxin-6-amine Chemical group O1C(F)(F)OC(F)(F)C2=CC(N)=CC=C21 ZENKESXKWBIZCV-UHFFFAOYSA-N 0.000 description 1
BNBRIFIJRKJGEI-UHFFFAOYSA-N 2,6-difluorobenzonitrile Chemical compound FC1=CC=CC(F)=C1C#N BNBRIFIJRKJGEI-UHFFFAOYSA-N 0.000 description 1
125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 1
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
ZSYMMINAALNVSH-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridine Chemical class C1=NC=CC2=NNN=C21 ZSYMMINAALNVSH-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
JOTRPRKONYTVBV-UHFFFAOYSA-N 4-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CN=CC=C1Cl JOTRPRKONYTVBV-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
101001047088 Canis lupus familiaris Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000011038 Cold agglutinin disease Diseases 0.000 description 1
241001459693 Dipterocarpus zeylanicus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000258241 Mantis Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
241000009328 Perro Species 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
241001310793 Podium Species 0.000 description 1
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
244000166490 Tetrameles nudiflora Species 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
ZKPUPHSBFMNFHO-UHFFFAOYSA-N [ClH]1C=CC=C1 Chemical compound [ClH]1C=CC=C1 ZKPUPHSBFMNFHO-UHFFFAOYSA-N 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000538 analytical sample Substances 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
125000004659 aryl alkyl thio group Chemical group 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000020345 childhood apraxia of speech Diseases 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000002895 emetic Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
125000004175 fluorobenzyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000000802 nitrating effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
208000014155 speech-language disorder-1 Diseases 0.000 description 1
239000001119 stannous chloride Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
150000008523 triazolopyridines Chemical class 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

PH40399A 1989-04-21 1990-04-19 Anticonvulsant compounds PH27118A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898909136A GB8909136D0 (en)	1989-04-21	1989-04-21	Anticonvulsant pyridines and analogues thereof

Publications (1)

Publication Number	Publication Date
PH27118A true PH27118A (en)	1993-03-16

Family

ID=10655494

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH40399A PH27118A (en)	1989-04-21	1990-04-19	Anticonvulsant compounds

Country Status (21)

Country	Link
EP (1)	EP0399653B1 (de)
JP (1)	JP2865367B2 (de)
KR (1)	KR0183972B1 (de)
AT (1)	ATE113046T1 (de)
CA (1)	CA2015047A1 (de)
CY (1)	CY2003B1 (de)
DD (1)	DD293823A5 (de)
DE (1)	DE69013396T2 (de)
DK (1)	DK0399653T3 (de)
ES (1)	ES2062351T3 (de)
FI (1)	FI93448C (de)
GB (1)	GB8909136D0 (de)
HK (1)	HK78397A (de)
HU (2)	HU206210B (de)
IE (1)	IE67335B1 (de)
IL (1)	IL94150A (de)
LV (1)	LV5780B4 (de)
NZ (1)	NZ233404A (de)
PH (1)	PH27118A (de)
PT (1)	PT93822B (de)
ZA (1)	ZA903021B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1087968A1 (de)	1998-06-16	2001-04-04	MERCK SHARP & DOHME LTD.	Triazolo-pyridin-derivate als liganden für gabarezeptoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3929812A (en) *	1974-05-20	1975-12-30	Squibb & Sons Inc	Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters
ES2051886T3 (es) *	1987-04-07	1994-07-01	Ciba Geigy Ag	Procedimiento para la obtencion de nuevos derivados de la 3h-1,2,3-triazolo(4,5-d)pirimidina.

1989
- 1989-04-21 GB GB898909136A patent/GB8909136D0/en active Pending
1990
- 1990-04-19 PH PH40399A patent/PH27118A/en unknown
- 1990-04-20 EP EP90304271A patent/EP0399653B1/de not_active Expired - Lifetime
- 1990-04-20 DK DK90304271.1T patent/DK0399653T3/da active
- 1990-04-20 NZ NZ233404A patent/NZ233404A/en unknown
- 1990-04-20 KR KR1019900005523A patent/KR0183972B1/ko not_active Expired - Fee Related
- 1990-04-20 FI FI901981A patent/FI93448C/fi not_active IP Right Cessation
- 1990-04-20 CA CA002015047A patent/CA2015047A1/en not_active Abandoned
- 1990-04-20 HU HU902502A patent/HU206210B/hu not_active IP Right Cessation
- 1990-04-20 IL IL9415090A patent/IL94150A/en not_active IP Right Cessation
- 1990-04-20 AT AT90304271T patent/ATE113046T1/de not_active IP Right Cessation
- 1990-04-20 ZA ZA903021A patent/ZA903021B/xx unknown
- 1990-04-20 DE DE69013396T patent/DE69013396T2/de not_active Expired - Fee Related
- 1990-04-20 PT PT93822A patent/PT93822B/pt not_active IP Right Cessation
- 1990-04-20 ES ES90304271T patent/ES2062351T3/es not_active Expired - Lifetime
- 1990-04-20 JP JP2105156A patent/JP2865367B2/ja not_active Expired - Lifetime
- 1990-04-20 IE IE140990A patent/IE67335B1/en not_active IP Right Cessation
- 1990-04-20 DD DD90339946A patent/DD293823A5/de not_active IP Right Cessation
1995
- 1995-05-11 HU HU95P/P00126P patent/HU211137A9/hu unknown
1996
- 1996-07-17 LV LV960252A patent/LV5780B4/xx unknown
1997
- 1997-06-12 HK HK78397A patent/HK78397A/en not_active IP Right Cessation
1998
- 1998-04-30 CY CY9802003A patent/CY2003B1/xx unknown

Also Published As

Publication number	Publication date
IE67335B1 (en)	1996-03-20
HU902502D0 (en)	1990-08-28
PT93822B (pt)	1996-09-30
JP2865367B2 (ja)	1999-03-08
ZA903021B (en)	1991-12-24
DK0399653T3 (da)	1994-11-14
AU626409B2 (en)	1992-07-30
KR900016208A (ko)	1990-11-12
DE69013396D1 (de)	1994-11-24
IE901409L (en)	1990-10-21
IL94150A (en)	1994-02-27
IL94150A0 (en)	1991-01-31
DD293823A5 (de)	1991-09-12
DE69013396T2 (de)	1995-05-04
EP0399653A1 (de)	1990-11-28
NZ233404A (en)	1992-08-26
EP0399653B1 (de)	1994-10-19
ATE113046T1 (de)	1994-11-15
CA2015047A1 (en)	1990-10-21
JPH02292286A (ja)	1990-12-03
HUT53905A (en)	1990-12-28
FI93448C (fi)	1995-04-10
FI901981A0 (fi)	1990-04-20
AU5372290A (en)	1990-10-25
CY2003B1 (en)	1998-04-30
PT93822A (pt)	1990-11-20
FI93448B (fi)	1994-12-30
LV5780B4 (lv)	1997-04-20
LV5780A4 (lv)	1996-12-20
HU211137A9 (en)	1995-10-30
HK78397A (en)	1997-06-20
ES2062351T3 (es)	1994-12-16
GB8909136D0 (en)	1989-06-07
HU206210B (en)	1992-09-28
KR0183972B1 (ko)	1999-05-01

Publication	Publication Date	Title
AU630251B2 (en)	1992-10-22	Dipyridodiazepines
AU742941B2 (en)	2002-01-17	Sustained release tablet formulation to treat parkinson disease
EP0828479B1 (de)	2001-10-24	Verfahren zur herstellung einer feststoffdespersion eines im wasser schwerlöslichen arzneimittel
SK404391A3 (en)	1995-08-09	3-imidazolymethyl-1,2,3,9-tetrahydro-4h-carbazole-4-on derivatives, method of their preparation and pharmaceutical agents containing this agents
DD297820A5 (de)	1992-01-23	Substituierte 9h-purine, verfahren zur herstellung derselben und ihre verwendung
KR100201509B1 (ko)	1999-06-15	1-(피리도(3,4-b-1,4-옥사지닐-4일-)-1h-인돌, 이를 위한 중간체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
JPH0372467A (ja)	1991-03-27	ピペラジン誘導体
US4095027A (en)	1978-06-13	2-Carbalkoxy-2'-aminocarbonyldiphenyl sulfides
PH27118A (en)	1993-03-16	Anticonvulsant compounds
FI66611B (fi)	1984-07-31	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenyl-kinolizidiner
US5240937A (en)	1993-08-31	Pharmaceutically active triazolopyridine compounds
JP3027762B2 (ja)	2000-04-04	抗痙攣性ピラジン
CA2358586A1 (en)	2000-07-13	Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors
PH26100A (en)	1992-02-06	N-pyrrol-1-yl)pyridinamines and their use as medicaments
US6310064B1 (en)	2001-10-30	Aralkyl diazabicycloalkane derivatives for CNS disorders
JPH09501954A (ja)	1997-02-25	イミダゾ［５，１−ｃ］［１，４］ベンゾキサジン−１−オンのイミダゾリルアルキル誘導体およびそれらの製造法
KR20040007658A (ko)	2004-01-24	역류성 질환에 유용한 신규 화합물
NZ234316A (en)	1992-03-26	4-h-indolo(1,2-d)(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine derivatives, preparation, intermediates and pharmaceutical compositions thereof
US5166209A (en)	1992-11-24	Pharmacologically active compounds
NL8701728A (nl)	1988-02-16	Heterocyclische verbindingen.
EP0534344B1 (de)	1995-02-15	Substituierte 3-Amino-2,3,4,5-Tetrahydro-1-Aryloxy-3-Benzazepine, Verfahren zu ihrer Herstellung und ihre Verwendung als Modulatoren der Neurotransmitterfunktion
US6656930B2 (en)	2003-12-02	Aralkyl diazabicycloalkane derivatives for CNS disorders
EP0390718A1 (de)	1990-10-03	Verfahren zur Herstellung von 1-Diphenylmethylpiperidin-Derivaten